All In Biotech

Drug Trial Radar · NCT04434092

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

A Phase III, Randomized, Open-label, Active-controlled, Multicenter Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

210

Actual

Start

Oct 8, 2020

Primary completion

Nov 16, 2022

Study completion Apr 18, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Jun 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH who have not been previously treated with complement inhibitor therapy.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • CrovalimabDrug

    Dosing depends on body weight. Participants will be dosed as follows: * 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study * 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study * 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study * 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study * 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study * 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study.

  • EculizumabDrug

    Eculizumab will be administered as specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Transfusion Avoidance (TA)Time frame: Baseline to Week 25
  2. Percentage of Participants With Hemolysis Control Measured by LDHTime frame: Week 5 to Week 25

Locations

63 sites in 23 countries. Site status is shown where the registry gives one.

  • Organizacion Medica de Investigacion (OMI)

    Ciudad Autonoma Buenos Aires, Argentina

  • Beneficencia Portuguesa de Sao Paulo

    São Paulo, Brazil

  • *X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia

    Santo André, São Paulo, Brazil

  • Peking Union Medical College Hospital

    Beijing, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China

  • The First Affiliated Hospital, Zhejiang University

    Hangzhou, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Affiliated Hospital of Nantong University

    Nantong, China

  • Huashan Hospital, Fudan University

    Shanghai, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • Hopital Claude Huriez - CHU Lille

    Lille, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bnite, Rhone, France

  • Universitaetsklinkm

    Essen, Germany

  • Universitaetsklinikum Ulm

    Ulm, Germany

  • General Hospital of Thessaloniki G. Papanikolaou

    Thessaloniki, Greece

  • Sapporo Medical University Hospital

    Hokkaido, Japan

  • University of Tsukuba Hospital

    Ibaraki, Japan

  • NTT Medical Center Tokyo

    Tokyo, Japan

  • Tokyo Medical University Hospital

    Tokyo, Japan

  • Vilnius University Hospital Santariskiu Clinics, Public Institution

    Vilnius, Lithuania

  • Hospital Tengku Ampuan Afzan

    Kuantan, Malaysia

  • Hospital Raja Permaisuri Bainun

    Ipoh, Perak, Malaysia

  • Hospital Pulau Pinang

    George Town, Pulau Pinang, Malaysia

  • Hospital Ampang

    Ampang, Selangor, Malaysia

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    Mexico City, Mexico CITY (federal District), Mexico

  • Global Trial Research Center S.A. de C.V.

    Monterrey, Nuevo León, Mexico

  • Amsterdam UMC, Locatie AMC

    Amsterdam, Netherlands

  • Mary Mediatrix Medical Center

    Lipa City, Philippines

  • Philippine General Hospital

    Manila, Philippines

  • St Lukes Medical Center

    Quezon, Philippines

  • Szpital Uniwersytecki nr2 im. dr J. Biziela

    Bydgoszcz, Poland

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • Samodzielny Publiczny Szpital Kliniczny nr 1

    Lublin, Poland

  • Pratia Poznan

    Skórzewo, Poland

  • MTZ Clinical Research Powered by Pratia

    Warsaw, Poland

  • Centro Hospitalar do Baixo Vouga E.P.E. - Hospital de Aveiro

    Aveiro, Portugal

  • Instituto Portugues Oncologia de Lisboa Francisco Gentil EPE

    Lisbon, Portugal

  • Centro Hospitalar do Porto - Hospital de Santo António

    Porto, Portugal

  • Spitalul Universitar de Urgenta Bucuresti

    Bucharest, Romania

  • Spitalul Clinic Municipal Filantropia Craiova

    Craiova, Romania

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.